

*Press Release*

*For Immediate Release*

May 23, 2007

## M's Science Corporation completes US\$ 7 Million Series D Financing

---

Kobe, Japan: May 23, 2007 - M's Science Corporation, a clinical stage discovery and development company announced today that it completed its Series D Preferred Stock financing in the amount of US\$ 7 million (JPY 800 million). The company has now raised a total of US\$36 million (JPY 4 billion) since its inception in 2000. The financing was led by JAFCO, Nomura Research and Advisory and several other leading Japanese venture capital funds.

S

M's Science will use the proceeds of this financing to advance the ongoing international clinical development of its two lead products SA4503, a sigma-1 receptor agonist, and HF10, an oncolytic virus. SA4503 has completed four Phase 1 studies in Europe and is in clinical development for the treatment of stroke and major depressive disorder. HF10 will enter into a Phase 1/2 trial in the United States for treatment of head and neck cancer.

"Completion of this round of financing is a validation of the potential of our development pipeline in cancer and central nervous system disorders. Proceeds from this financing will allow M's Science to fully explore the potential of these products in Europe and in the United States," commented Mr. Akihiko Shimauchi, President and COO. "SA4503 and HF10 represent truly novel approaches to the treatment of serious diseases. These funds will enable us to rapidly progress our lead products SA4503 and HF10 towards clinical proof-of-concept" said Dr. Shiro Mita, Chairman and CEO.

### **About M's Science Corp.**

M's Science is a privately held biopharmaceutical company dedicated to the discovery and development of treatments of central nervous system (CNS) disorders and cancer. MSC is currently developing two clinical stage products.

SA4503 is a potent and selective agonist of the sigma-1 receptor. SA4503 enhances neuroregeneration by activation of plasticity pathways and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. In addition, SA4503 has neuromodulatory and cognitive enhancer activities. This product profile is unique and SA4503 thus provides a novel opportunity towards therapy of various CNS disorders. M's Science will initially focus its clinical development of SA4503 on the enhancement of recovery from stroke and on the treatment of major depressive disorder.

HF10 is a natural isolate of an attenuated herpes simplex virus and possesses strong tumor killing ability. HF10 is administered intratumorally thus limiting or eliminating adverse effects commonly observed with cytotoxic therapy. HF10's activity in patients with breast or head & neck cancer has been demonstrated in studies conducted in collaboration with the University of Nagoya. M's Science initially develops HF10 for the treatment of head & neck cancer and intends to expand its application to other cancers.

---

**Contact**

M's Science Corporation

Address: 5-5-2, Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan

Tel: +81-78-388-6000 Fax: +81-78-388-6001

E-mail: [info@m-sci.com](mailto:info@m-sci.com)